Literature DB >> 18215383

[Maxillary sinus cancer review in 23 patients treated with postoperative radiotherapy].

Rubén D Manrique1, Leopoldo G Deive, Michel A Uehara, Roslyn K Manrique, José L Rodríguez, Carmelo Santidrian.   

Abstract

OBJECTIVE: To describe the survival and outcome of maxillary sinus cancer in patients managed with surgery and post-operative radiotherapy during the last 10 years in our hospital. PATIENTS AND
METHOD: Descriptive, retrospective, non-randomized study of 23 patients with cancer of the maxillary sinus managed at the Vigo University Hospital Complex, Spain, with radical surgery and post-operative radiotherapy, between 1995 and 2004.
RESULTS: The 3-year actuarial survival was 47.8% and the adjusted actuarial survival was 60.8%. Permanent local tumour control was achieved in 60.8% of cases (14/23). Local tumour recurrence was the main cause of treatment failure (33.3%; 4/12). The most significant prognostic factors affecting local tumour control and survival were: clinical stage (P< .031), suprastructural location of the tumour (P< .001), and presence of positive resection margins (P< .001).
CONCLUSIONS: Local recurrence was found to be very high and generally the main cause of death. New treatment protocols should be assessed.

Entities:  

Mesh:

Year:  2008        PMID: 18215383

Source DB:  PubMed          Journal:  Acta Otorrinolaringol Esp        ISSN: 0001-6519


  3 in total

1.  Carcinoma of Maxillary Sinus Masquerading as Odontogenic Infection.

Authors:  Ashir Kolikkal Ramachamparambathu; Manoj Vengal; Abdulla Mufeed; Nizaro Siyo; Anis Ahmed
Journal:  J Clin Diagn Res       Date:  2016-09-01

2.  Results of Treatment of Squamous Cell Carcinoma of Maxillary Sinus: A 26-Year Experience.

Authors:  M Ashraf; J Biswas; A Dam; A Bhowmick; V Sing; S Nayak
Journal:  World J Oncol       Date:  2010-02-01

3.  Carcinoma of the Maxillary Antrum: A Case Report.

Authors:  N M Praveena; Gopla Maragathavalli
Journal:  Cureus       Date:  2018-05-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.